Ionis Pharmaceuticals, Inc. (IONS)Healthcare | Biotechnology | Carlsbad, United States | NasdaqGS
74.78 USD
-0.09
(-0.120%) ⇩
(April 21, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | April 19, 2026, 1:12 a.m. EDT
Ionis is a classic 'long-term print-and-fold' with massive downside protection built into the options chain via heavy 2026/2027 put buying around $65-$90. While the fundamental story on their 2026 catalyst pipeline supports a higher price over multi-years, the immediate options architecture is defensive, reflecting skepticism that the stock can rally aggressively above $80 in the near term despite the 'buy' analyst rating. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.065956 |
| AutoETS | 0.067413 |
| AutoARIMA | 0.067414 |
| MSTL | 0.068108 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 14.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.159 |
| Excess Kurtosis | -1.39 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 534.844 |
| Revenue per Share | 5.898 |
| Market Cap | 12,353,058,816 |
| Forward P/E | -121.81 |
| Beta | 0.40 |
| Profit Margins | -40.41% |
| Website | https://www.ionis.com |
As of April 19, 2026, 1:12 a.m. EDT: Despite significant volume in long-dated OTM calls (2027+ decade) above key multiples (100, 110, 115), speculative positioning is heavily skewed towards downside protection. There are massive 'walled' otm put positions sitting at 65, 67.5, and 85 strikes for the 2026-07 calendar. This creates a high hedge ratio where bulls are synthetically short via sales of far OTM calls. The short-term IV profile for May 2026 shows a massive volume/oi imbalance at 70.0 (volume 1.2k, oti 1), suggesting a bet on volatility near the 72-73 price level.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5697594 |
| Address1 | 2,855 Gazelle Court |
| All Time High | 86.74 |
| All Time Low | 2.5 |
| Ask | 74.93 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,510,280 |
| Average Daily Volume3 Month | 2,103,103 |
| Average Volume | 2,103,103 |
| Average Volume10Days | 1,510,280 |
| Beta | 0.4 |
| Bid | 74.64 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 2.995 |
| City | Carlsbad |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 74.78 |
| Current Ratio | 3.826 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 75.96 |
| Day Low | 73.8 |
| Debt To Equity | 534.844 |
| Display Name | Ionis Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,465,800 |
| Earnings Call Timestamp Start | 1,777,465,800 |
| Earnings Timestamp | 1,777,465,800 |
| Earnings Timestamp End | 1,777,465,800 |
| Earnings Timestamp Start | 1,777,465,800 |
| Ebitda | -369,236,992 |
| Ebitda Margins | -0.39126 |
| Enterprise To Ebitda | -33.281 |
| Enterprise To Revenue | 13.021 |
| Enterprise Value | 12,288,475,136 |
| Eps Current Year | -3.32714 |
| Eps Forward | -0.6139 |
| Eps Trailing Twelve Months | -2.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 76.7344 |
| Fifty Day Average Change | -1.9543991 |
| Fifty Day Average Change Percent | -0.02546966 |
| Fifty Two Week Change Percent | 156.97594 |
| Fifty Two Week High | 86.74 |
| Fifty Two Week High Change | -11.959999 |
| Fifty Two Week High Change Percent | -0.13788332 |
| Fifty Two Week Low | 28.79 |
| Fifty Two Week Low Change | 45.989998 |
| Fifty Two Week Low Change Percent | 1.5974295 |
| Fifty Two Week Range | 28.79 - 86.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 674,487,000,000 |
| Float Shares | 163,906,817 |
| Forward Eps | -0.6139 |
| Forward P E | -121.81136 |
| Free Cashflow | -154,724,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,402 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.01291 |
| Gross Profits | 12,183,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00719 |
| Held Percent Institutions | 1.05851 |
| Implied Shares Outstanding | 165,192,011 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California. |
| Long Name | Ionis Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 12,353,058,816 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_30300 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -381,387,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,367,925,863 |
| Number Of Analyst Opinions | 22 |
| Open | 75.87 |
| Operating Cashflow | -268,583,008 |
| Operating Margins | -1.0547299 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 27.33 |
| Phone | 760 931 9200 |
| Previous Close | 74.87 |
| Price Eps Current Year | -22.47576 |
| Price Hint | 2 |
| Price To Book | 24.96828 |
| Price To Sales Trailing12 Months | 13.089875 |
| Profit Margins | -0.40414003 |
| Quick Ratio | 3.514 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.82609 |
| Region | US |
| Regular Market Change | -0.090004 |
| Regular Market Change Percent | -0.120214 |
| Regular Market Day High | 75.96 |
| Regular Market Day Low | 73.8 |
| Regular Market Day Range | 73.8 - 75.96 |
| Regular Market Open | 75.87 |
| Regular Market Previous Close | 74.87 |
| Regular Market Price | 74.78 |
| Regular Market Time | 1,776,801,601 |
| Regular Market Volume | 1,722,488 |
| Return On Assets | -0.07309 |
| Return On Equity | -0.70795 |
| Revenue Growth | -0.103 |
| Revenue Per Share | 5.898 |
| Sand P52 Week Change | 0.3140242 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 165,192,011 |
| Shares Percent Shares Out | 0.0868 |
| Shares Short | 14,330,826 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 15,323,236 |
| Short Name | Ionis Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.113800004 |
| Short Ratio | 6.21 |
| Source Interval | 15 |
| State | CA |
| Symbol | IONS |
| Target High Price | 130.0 |
| Target Low Price | 47.0 |
| Target Mean Price | 98.31818 |
| Target Median Price | 104.0 |
| Total Cash | 2,680,448,000 |
| Total Cash Per Share | 16.226 |
| Total Debt | 2,615,865,088 |
| Total Revenue | 943,710,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 68.4272 |
| Two Hundred Day Average Change | 6.3527985 |
| Two Hundred Day Average Change Percent | 0.092840254 |
| Type Disp | Equity |
| Volume | 1,722,488 |
| Website | https://www.ionis.com |
| Zip | 92,010 |